摘要
目的:探讨卵巢上皮性癌组织中雷帕霉素靶蛋白(mTOR)与真核生物翻译起始因子4E结合蛋白1(4EBP1)磷酸化的表达情况及与临床病理特征相关性。方法:通过免疫组织化学染色法检测卵巢癌组织中mTOR及P-4EBP1的表达情况,利用SPSS18.0软件分析mTOR和P-4EBP1蛋白表达与卵巢癌临床病理特征及预后的相关性。结果:卵巢癌组织中存在mTOR和P-4EBP1蛋白异常高表达,阳性表达率分别为55.92%(85/152),61.28%(93/152);mTOR蛋白在卵巢癌临床Ⅲ~Ⅳ期的表达高于临床Ⅰ~Ⅱ期(P<0.05);mTOR和P-4EBP1蛋白在淋巴结转移卵巢癌组织中阳性表达率显著高于无淋巴结转移卵巢癌组织(P<0.05);随访死亡患者的卵巢癌组织中P-4EBP1蛋白阳性表达率显著高于存活患者的卵巢癌组织(P<0.05)。结论:mTOR和P-4EBP1蛋白过表达可能与卵巢癌的发生、发展及不良预后密切相关,mTOR和P-4EBP1有望成为卵巢癌临床诊治和判断预后独特的分子标志物。
Objective: To investigate the association between the expression of mTOR and phospho-eIF4E-binding protein 1(P-4EBP1) and clinicopathological features in epithelial ovarian cancer. Methods: The expression of mTOR and P-4EBP1 proteins were detected by immunohistochemistry method in ovarian cancer tissue, and the association between the expression of mTOR and P-4EBP1 proteins and clinicopathological features and prognostic implications in ovarian cancer were analyzed by SPSS18.0. Results: The positive percentage of mTOR and P-4EBP1 proteins expression in ovarian cancer were 55.92%(85/152) and 61.28%(93/152), respectively. In the clinical stages of epithelial ovarian cancer, the positive expression rate of mTOR and P-4EBP1 proteins in high-grade group(gradeⅢ+Ⅳ) were obviously higher than the rate in low-grade group(gradeⅠ+Ⅱ)(P<0.05). There was significantly higher expression of mTOR and P-4EBP1 proteins in lymph node metastasis than no lymph node metastasis in ovarian cancer(P<0.05). The expression of P-4EBP1 proteins in group of dead patients were significantly higher than that in the group of live patients in ovarian cancer(P<0.05). Conclusion: The over-expression of mTOR and P-4EBP1 proteins may be closely related to the occurrence, development and adverse prognosis of ovarian cancer. Hence, mTOR and P-4EBP1 proteins are expected to be unique molecular markers for clinical diagnosis and prognosis of ovarian cancer.
作者
张春燕
栗学清
张毅强
裴晋红
靳双玲
郑军
Zhang Chunyan;Li Xueqing;Zhang Yiqiang(Department of Gynaecology and Obstetrics,Peace Hospital Affiliated to Changzhi Medical College)
出处
《长治医学院学报》
2019年第5期326-329,共4页
Journal of Changzhi Medical College
基金
山西省高等学校科技创新项目(2019L0688)
